Laddar...
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a difficult to treat cancer characterized by poor tumor immunity with only one approved systemic drug, sorafenib. If novel combination treatments are to be developed with immunological agents, the effects of sorafenib on tumor immunity are important to understand. I...
Sparad:
| Huvudupphovsmän: | , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer-Verlag
2012
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3863727/ https://ncbi.nlm.nih.gov/pubmed/23223899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1380-8 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|